Coherus Oncology Income Statement (2012-2025) | CHRS

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Mar2021	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025
Revenue & cost
Revenue (Quarter)	83.03M	87.64M	82.50M	73.37M	60.12M	60.15M	45.42M	45.35M	32.44M	58.72M	74.57M	91.52M	2.31M	10.30M	6.05M	7.73M	7.60M	10.25M	11.57M	12.75M
Cost of Revenue (Quarter)	7.51M	16.70M	21.28M	12.10M	9.37M	11.28M	35.23M	14.20M	16.87M	24.85M	32.70M	84.57M	1.44M	1.81M	2.73M	2.75M	2.65M	3.40M	3.72M	4.04M
Gross Profit (Quarter)	75.52M	70.95M	61.22M	61.27M	50.74M	48.87M	10.19M	31.15M	15.56M	33.87M	41.87M	6.96M	0.87M	8.49M	3.32M	4.98M	4.95M	6.86M	7.85M	8.70M
Operating items
Research & Development (Quarter)	11.50M	54.77M	54.09M	50.76M	82.92M	41.61M	45.81M	29.02M	34.15M	23.27M	25.65M	26.37M	28.42M	20.60M	22.05M	20.76M	24.36M	26.31M	27.25M	30.97M
Selling, General & Administrative (Quarter)	39.39M	40.34M	39.92M	50.05M	48.75M	51.28M	44.83M	53.62M	49.15M	45.14M	48.22M	49.49M	40.23M	27.52M	28.13M	29.61M	26.02M	26.04M	24.93M	23.61M
Other Operating Expenses (Quarter)	199.50M	16.70M	21.28M	12.10M	9.37M	11.28M	-108.47M	-78.10M	16.87M	24.85M	-49.98M	-79.65M	1.44M	1.81M	2.73M	2.75M	2.65M	3.40M	3.72M	4.04M
Operating Expenses (Quarter)	250.39M	111.81M	115.29M	112.92M	141.04M	104.16M	125.87M	96.84M	100.18M	93.26M	106.57M	160.43M	70.09M	49.92M	52.91M	53.12M	53.03M	55.74M	55.90M	58.63M
Operating Income (Quarter)	-167.36M	-24.16M	-32.79M	-39.55M	-80.92M	-44.01M	-80.45M	-51.49M	-67.75M	-34.54M	-32.01M	-68.91M	-67.79M	-39.63M	-46.86M	109.04M	-45.44M	-45.49M	-44.33M	-45.88M
EBIT (Quarter)	-167.36M	-24.16M	-32.79M	-39.55M	-80.92M	-44.01M	-80.45M	-51.49M	-67.75M	-34.54M	-32.01M	-68.91M	-67.79M	-39.63M	-46.86M	109.04M	-45.44M	-45.49M	-44.33M	-45.88M
Non-operating items
Other Non Operating Income (Quarter)	0.06M	0.01M	0.03M	-0.39M	0.03M	0.44M	1.34M	10.04M	1.73M	1.62M	2.25M	-0.13M	2.87M	-12.63M	2.08M	-19.05M	0.19M	2.90M	2.14M	-5.23M
Non Operating Income (Quarter)	0.06M	0.01M	0.03M	-0.39M	0.03M	0.44M	1.34M	2.01M	1.73M	1.62M	2.25M	-0.13M	2.87M	1.47M	2.08M	1.20M	0.19M	2.90M	2.14M	1.78M
Net income details
EBT (Quarter)	-172.95M	-29.90M	-38.53M	-45.68M	-96.08M	-50.15M	-86.65M	-58.86M	-75.73M	-42.87M	-40.02M	-79.65M	-68.04M	-54.85M	-47.60M	-46.09M	-47.40M	-44.86M	-44.52M	-46.35M
Tax Provisions (Quarter)											-0.38M
Profit After Tax (Quarter)	-172.95M	-29.90M	-38.53M	-45.73M	-96.08M	-50.15M	-86.65M	-58.87M	-75.73M	-42.87M	-39.64M	-79.65M	102.88M	-12.92M	-47.60M	197.81M	-56.57M	297.77M	-35.53M	-37.64M
Income from Non-Controlling Interests (Quarter)
Income from Continuing Operations (Quarter)	-172.95M	-29.90M	-38.53M	-45.68M	-96.08M	-50.15M	-86.65M	-58.86M	-75.73M	-42.87M	-39.64M	-79.65M	-68.04M	-54.85M	-47.60M	-46.09M	-47.40M	-44.86M	-44.52M	-46.35M
Consolidated Net Income (Quarter)	-172.95M	-29.90M	-38.53M	-45.68M	-96.08M	-50.15M	-86.65M	-58.86M	-75.73M	-42.87M	-39.64M	-79.65M	170.91M	41.93M	36.85M	-4.60M	-9.17M	342.63M	8.99M	8.70M
Income towards Parent Company (Quarter)	-172.95M	-29.90M	-38.53M	-45.68M	-96.08M	-50.15M	-86.65M	-58.86M	-75.73M	-42.87M	-39.64M	-79.65M	170.91M	41.93M	36.85M	-4.60M	-9.17M	342.63M	8.99M	8.70M
Net Income towards Common Stockholders (Quarter)	-172.95M	-29.90M	-38.53M	-45.68M	-96.08M	-50.15M	-86.65M	-58.86M	-75.73M	-42.87M	-39.64M	-79.65M	170.91M	41.93M	36.85M	-4.60M	-9.17M	342.63M	8.99M	8.70M
Additional items
EPS (Basic) (Quarter)	-2.37	-0.40	-0.49	-0.59	-1.24	-0.65	-1.11	-0.76	-0.96	-0.49	-0.41	-0.74	-0.60	-0.11	-0.09	1.73	-0.49	-0.39	-0.31	-3.33
EPS (Weighted Average and Diluted) (Quarter)	-2.37	-0.40	-0.49	-0.59	-1.24	-0.65	-1.11	-0.76	-0.96	-0.49	-0.41	-0.74	0.91	-0.48	-0.41	-0.44	-0.49	-0.39	-0.38	-0.34
Shares Outstanding (Weighted Average) (Quarter)	72.83M	74.20M	74.98M	75.45M	77.25M	77.41M	77.52M	77.63M	79.27M	87.27M	97.74M	94.16M	112.75M	114.82M	115.21M	114.55M	115.86M	116.08M	116.23M	117.14M
Shares Outstanding (Diluted Average) (Quarter)	72.83M	74.20M	74.98M	75.45M	77.25M	77.55M	77.52M	77.63M	79.27M	87.27M	88.28M	94.16M	112.75M	114.82M	115.21M	114.55M	115.86M	116.08M	116.06M	117.14M
EBITDA (Quarter)	-167.36M	-24.16M	-32.79M	-39.55M	-80.92M	-44.01M	-80.45M	-51.49M	-67.75M	-34.54M	-32.01M	-68.91M	-67.79M	-39.63M	-46.86M	109.04M	-45.44M	-45.49M	-44.33M	-45.88M
Interest Expenses (Quarter)	5.65M	5.75M	5.77M	5.79M	8.97M	6.58M	7.54M	9.38M	9.71M	9.94M	10.27M	10.62M	3.12M	4.06M	2.83M	1.91M	2.15M	2.28M	2.33M	2.25M
Tax Rate (Quarter)											0.95%

Research Tools

Coherus Oncology Income Statement (2012-2025) | CHRS

Create an account

Sign In

Reset Password